𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝘄𝗲 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹𝗹𝘆 𝗮𝗰𝘁𝗶𝘃𝗮𝘁𝗲 𝘁𝗵𝗲 𝘁𝘂𝗺𝗼𝗿 𝘀𝘂𝗽𝗽𝗿𝗲𝘀𝘀𝗼𝗿 𝗥𝗯?
At first glance, that sounds paradoxical. But it’s the question that emerged as we began mapping endogenous Rb across the genome after CDK4/6 inhibition. Excited to share our work, now published in @nature.com
🧵1/6
